Tiansheng Pharmaceutical Group Co Ltd

Tiansheng Pharmaceutical Group Co Ltd has a market price of 5.39 CNY per share, with a market capitalization of 1.71 billion CNY. The company's price-to-book ratio is 0.88, and its price-to-tangible-book ratio is also 0.88, indicating that the company is trading at a discount to its book value. The enterprise value to EBITDA ratio is negative at -34.06, reflecting the company's current operating losses. The enterprise value to revenue ratio is 4.19, suggesting that the company is valued at a moderate multiple of its revenue. The company's profitability is weak, with a return on equity of -2.84% and a return on assets of -2.1%, both of which are below the industry median for pharmaceutical companies. The company reported a net loss of 55.42 million CNY and an operating loss of 63.26 million CNY in the latest period. The gross profit margin is 47.1%, which is in line with the industry average, but the operating margin is negative, indicating that the company is struggling to convert revenue into operating profit. Tiansheng Pharmaceutical Group Co Ltd's revenue is concentrated in the domestic Chinese market, with no significant international operations disclosed in the available data. The company's revenue concentration in a single geographic region increases its exposure to local economic and regulatory risks. The company's business is primarily driven by its pharmaceutical products, with no material diversification into other segments. The company's growth trajectory is uncertain, with no specific revenue growth targets or projections provided in the available data. The company's operating cash flow is positive at 42.97 million CNY, but its free cash flow is low at 4.92 million CNY, indicating limited cash generation after capital expenditures. The company's capital expenditures were 26.92 million CNY in the latest period, suggesting a modest investment in long-term assets. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The company has a debt-to-equity ratio of 0.23, indicating a relatively low level of leverage. However, the company's net cash position is negative after subtracting total debt, which could pose a liquidity challenge in the event of a cash flow disruption. The company has not disclosed any recent dilutive events, and its diluted shares outstanding are equal to its basic shares, suggesting no material dilution pressure. The company has not disclosed any recent material events, such as regulatory actions, product launches, or strategic partnerships, in the available data. The absence of recent events suggests a stable but unremarkable operational environment.